Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496286 | 0.84 | HTT (0.46) | HTTCYP1A2CYP2C19SLC22A12NCF1 | |
| SCHEMBL4467255 | 0.76 | ALDH1A1 (0.46) | CYP1A2CYP2C19BACE1CCNB2CDK1 | |
| SCHEMBL4455873 | 0.76 | NR4A2 (0.43) | CYP1A2CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL856993 | 0.76 | CCNC (0.35) | BACE1CCNB2CDK1CCNB1GSK3A | |
| SCHEMBL1451142 | 0.76 | ALDH1A1 (0.41) | HTTCCNB2CDK1CCNB1GSK3A | |
| SCHEMBL5750340 | 0.72 | NOS3 (0.39) | HTTCYP1A2CDK8LMNASMN1; SMN2 | |
| SCHEMBL5748480 | 0.72 | ALDH1A1 (0.34) | LMNASMN1; SMN2 | |
| SCHEMBL590041 | 0.72 | LMNA (0.43) | CYP1A2NCF1LMNASMN1; SMN2GAK | |
| SCHEMBL5749391 | 0.72 | CDK5 (0.37) | CYP1A2SLC22A12ALKCCNB2CDK1 | |
| SCHEMBL28843537 | 0.72 | ALDH1A1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2083819-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2017-02-22 | — | — | EP | disclosed |
| US-8278327-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110021509-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-01-27 | — | — | US | disclosed |
| US-7786139-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| WO-2009143178-A2 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20080300240-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300240-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | HTT 769/4885CYP1A2 1182/4885CYP2C19 307/4885 |
| US-20110021509-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | HTT 681/4885CYP1A2 1256/4885CYP2C19 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.